{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-24-002612","form_type":"8-K","ticker":"ALGS","cik":"0001799448","company_name":"Aligos Therapeutics, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.169581+00:00","generated_at":"2026-06-02T19:37:13.833225+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aligos Q1 net loss $34.9M; Phase 2a HERALD study commenced, topline expected Q4 2024","bullets":["Net loss of $34.9M ($0.22 per share) vs $23.0M ($0.53) in Q1 2023; increase due to non-cash warrant liability charge.","Cash and investments $112.7M, down from $135.7M at Dec 2023; runway through end of 2025.","Phase 2a HERALD study (ALG-055009 for MASH) started dosing April 2024; topline data expected Q4 2024.","Received additional $1.3M NIH grant for pan-coronavirus protease inhibitor ALG-097558; Phase 2 enabling activities underway."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-24-002612","json":"https://secwatch.observer/filing/0001171843-24-002612.json","markdown":"https://secwatch.observer/filing/0001171843-24-002612.md","text":"https://secwatch.observer/filing/0001171843-24-002612.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799448/000117184324002612/0001171843-24-002612-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799448/000117184324002612/f8k_050724.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T19:37:13.833225+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ade3237e78491f4dac5685a9e813b7dfbdae7707","claim":"Aligos Therapeutics, Inc. reported first quarter 2024 results: net income Net losses for the three months ended March 31, 2024 were $34.9 million, EPS basic and diluted net loss per common share of $(0.22).","evidence_excerpt":"Net losses for the three months ended March 31, 2024 were $34.9 million or basic and diluted net loss per common share of $(0.22), compared to net losses of $23.0 million or basic and diluted net loss per common share of $(0.53) for the three months ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799448/000117184324002612/0001171843-24-002612-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2024"},{"label":"Net income","value":"Net losses for the three months ended March 31, 2024 were $34.9 million"},{"label":"EPS","value":"basic and diluted net loss per common share of $(0.22)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}